Pharma BD Deal Intelligence

Novartis AG / IFM Tre, Inc.

2019 · Acquisition/Merger · $1.6B · Complete

Announcement Sentiment

100

Strongly positive

Novartis acquired IFM Therapeutics' subsidiary IFM Tre for $310M upfront plus up to $1.265B in contingent milestones. Adds three preclinical NLRP3 antagonist programs (oral systemic, gut-targeted, CNS-penetrant) for inflammatory diseases.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced Apr 01, 2019
Closed Apr 25, 2019
Deal value $1.6B
Deal type Acquisition/Merger
Therapeutic area Inflammatory diseases (gout, NASH, atherosclerosis)
Indications Inflammatory diseases (gout, NASH, atherosclerosis)
Key assets NLRP3 antagonist programs
Mechanism NLRP3 inflammasome antagonists

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals